Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(10 months from now) | |
US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(5 years from now) | |
US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(6 years from now) | |
US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC